| DIRECT COMPETITOR COMPARISON | |
| CYTX | ASTM | BAX | OSIR | Industry | | Market Cap: | 237.94M | 56.98M | 34.18B | 229.08M | 98.96M | | Employees: | 88 | 48 | 48,500 | 158 | 65 | | Qtrly Rev Growth (yoy): | -40.00% | 170.40% | -0.20% | 963.70% | 19.70% | | Revenue (ttm): | 14.01M | 228.00K | 12.22B | 39.94M | 14.01M | | Gross Margin (ttm): | 90.75% | 38.60% | 51.23% | 100.00% | 65.68% | | EBITDA (ttm): | -15.20M | -15.29M | 3.37B | -37.37M | -12.30M | | Oper Margins (ttm): | -120.28% | -7,002.63% | 22.54% | -95.24% | -137.11% | | Net Income (ttm): | -20.26M | -15.83M | 2.20B | -35.19M | N/A | | EPS (ttm): | -0.605 | -0.105 | 3.562 | -0.273 | -0.31 | | P/E (ttm): | N/A | N/A | 15.92 | N/A | 17.26 | | PEG (5 yr expected): | N/A | N/A | 1.3 | N/A | 1.28 | | P/S (ttm): | 16.44 | 243.03 | 2.79 | 5.86 | 9.45 |
|
| ASTM = Aastrom Biosciences, Inc. | | BAX = Baxter International Inc. | | OSIR = Osiris Therapeutics, Inc. | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.85 | 0.53% | 57.54B | 12.40 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.18 | 1.69% | 13.93B | 16.12 | | Genzyme Corp. | GENZ | 49.98 | -0.58% | 13.26B | 28.49 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.59 | 0.71% | 41.93B | 18.02 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.64 | 0.78% | 9.03B | 1033.47 | | Teva Pharmaceutical Industries Limited | TEVA | 54.01 | 0.82% | 47.58B | 49.41 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.90 | 1.64% | 4.02B | 19.54 | | King Pharmaceuticals Inc. | KG | 11.72 | 0.43% | 2.91B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.99 | -1.15% | 5.50B | 110.37 | | Pfizer Inc. | PFE | 18.49 | -0.80% | 149.21B | 15.36 | | Johnson & Johnson | JNJ | 64.36 | 0.31% | 177.58B | 14.06 | | GlaxoSmithKline plc | GSK | 42.75 | 0.73% | 108.37B | 13.49 | | Sanofi-Aventis | SNY | 39.38 | -0.35% | 102.83B | N/A | | Novartis AG | NVS | 55.55 | -0.41% | 126.17B | 16.63 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.42 | -1.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.30 | 1.49% | 67.13B | 9.30 | | Abbott Laboratories | ABT | 53.78 | -0.85% | 83.18B | 14.57 | | Bristol-Myers Squibb Co. | BMY | 25.14 | -0.08% | 49.80B | 13.01 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | BAX | | Baxter Receives H1N1 Vaccine Order
Fri, Dec 4 -
Zacks.com | | • | BAX | | Slovenia to buy 10,000 H1N1 vaccines from Baxter
Thu, Dec 3 -
at Reuters | | • | BAX | | RPT-UPDATE - EU: no safety concerns as 10 mln get H1N1 shots
Thu, Dec 3 -
at Reuters | | • | ASTM | | Geron, StemCells: Late Day Volume Plays
Wed, Dec 2 -
at TheStreet.com | | • | ASTM | | Stem Cell Stocks Explode Higher on NIH Announcement
Wed, Dec 2 -
Indie Research | | • | OSIR | | Embryonic stem cells, the ultimate master cell
Wed, Dec 2 -
at Reuters | | • | OSIR | | UM study: Stem cells help heart patients
Mon, Nov 30 -
at bizjournals.com | | • | BAX | | 8 HealthCare Stocks With 3%+ Dividends
Sun, Nov 29 -
at Seeking Alpha | | • | BAX | | 10 Dividend Picks For Your Portfolio: Chief Investors
Wed, Nov 25 -
at CNBC | | • | BAX | | [video] The Dividend Strategy
Wed, Nov 25 -
at CNBC | | • | OSIR | | Osiris Therapeutics to Present at Piper Jaffray Healthcare Conference
Wed, Nov 25 -
Business Wire | | • | BAX | | Becton Acquires HandyLab
Mon, Nov 23 -
Zacks.com | | • | OSIR | | Medical Products Maker Has High Hopes For New Bone Treatment
Fri, Nov 20 -
Investor's Business Daily | | • | OSIR | | Expiration Trade Behind Osiris Activity
Fri, Nov 20 -
at Seeking Alpha | | • | BAX | | 30 High Yielding Option Write Ideas for November Option Expiration Friday
Fri, Nov 20 -
at Seeking Alpha | | • | BAX | | Healthcare Spin Off Companies Offer Opportunity To Investors According To Credit Suisse Senior Analyst
Thu, Nov 19 -
Wall Street Transcript | | • | OSIR | | Genzyme's Termeer: Worst Biotech CEO of '09
Tue, Nov 17 -
at TheStreet.com | | • | ASTM | | Updates and Results From Aastrom's Vascular Program Presented at an American Heart Association Satellite Symposium
Mon, Nov 16 -
GlobeNewswire | | • | ASTM | | Interim Results From Aastrom's IMPACT-DCM Cardiac Trial Presented at The American Heart Association Meeting
Mon, Nov 16 -
GlobeNewswire | | • | ASTM | | AASTROM BIOSCIENCES INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | | All Headlines for these symbols... |
|
|
|
0.22% Nasdaq 
Competitors
